Kelly E. Tenzek, Huei-Yen Winnie Chen, Laura A. Brady, Connor Wurst, Matt Cosmai, Jennifer Carlson, Andrew Baumgartner, Ranjit Singh, Robert G. Wahler Jr., Scott Monte
{"title":"Doctor–Patient Deprescribing Conversations: A Multidisciplinary Analysis of Quality Assurance Recordings","authors":"Kelly E. Tenzek, Huei-Yen Winnie Chen, Laura A. Brady, Connor Wurst, Matt Cosmai, Jennifer Carlson, Andrew Baumgartner, Ranjit Singh, Robert G. Wahler Jr., Scott Monte","doi":"10.1111/bcpt.70122","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Previous work in deprescribing interactions primarily involved surveys, interviews or reviews; there is a gap in utilizing real-time doctor–patient communication to understand what strategies physicians use to deprescribe and how patients respond. To move research methodology in this direction, our multidisciplinary team brought together professionals from biomedical, cognitive and social sciences to collaborate with a primary care practice and analyse nine quality-assurance recordings of doctor–patient visits. Eligible patients were 60 years or older and prescribed two or more medications. Through collaborative mixed-method analysis, we identified outcomes and themes of deprescribing conversations. An additional layer of analysis was conducted based on qualitative interviews with two deprescribing physicians for a conversation about physicians' decision-making process in initiating and responding to patient concerns in the interaction. Interplay between patient, physician and system factors was noted, highlighting the key role of health care team collaboration to support deprescribing. Our innovative research design enables a better understanding of deprescribing processes in a primary care setting and has implications for future research including patients, caregivers and community providers.</p>\n </div>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"137 5","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Basic & Clinical Pharmacology & Toxicology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/bcpt.70122","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Previous work in deprescribing interactions primarily involved surveys, interviews or reviews; there is a gap in utilizing real-time doctor–patient communication to understand what strategies physicians use to deprescribe and how patients respond. To move research methodology in this direction, our multidisciplinary team brought together professionals from biomedical, cognitive and social sciences to collaborate with a primary care practice and analyse nine quality-assurance recordings of doctor–patient visits. Eligible patients were 60 years or older and prescribed two or more medications. Through collaborative mixed-method analysis, we identified outcomes and themes of deprescribing conversations. An additional layer of analysis was conducted based on qualitative interviews with two deprescribing physicians for a conversation about physicians' decision-making process in initiating and responding to patient concerns in the interaction. Interplay between patient, physician and system factors was noted, highlighting the key role of health care team collaboration to support deprescribing. Our innovative research design enables a better understanding of deprescribing processes in a primary care setting and has implications for future research including patients, caregivers and community providers.
期刊介绍:
Basic & Clinical Pharmacology and Toxicology is an independent journal, publishing original scientific research in all fields of toxicology, basic and clinical pharmacology. This includes experimental animal pharmacology and toxicology and molecular (-genetic), biochemical and cellular pharmacology and toxicology. It also includes all aspects of clinical pharmacology: pharmacokinetics, pharmacodynamics, therapeutic drug monitoring, drug/drug interactions, pharmacogenetics/-genomics, pharmacoepidemiology, pharmacovigilance, pharmacoeconomics, randomized controlled clinical trials and rational pharmacotherapy. For all compounds used in the studies, the chemical constitution and composition should be known, also for natural compounds.